

APPENDIX
U.S. Serial No. *To Be Assigned* (Docket 2836-E)
Pending Claims

12. (amended) A method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) transfecting the dendritic cells with a gene encoding antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

13. (amended) A method according to claim 12, further comprising contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.

15. (new) A method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

16. (new) The method according to claim 15 further comprising contacting the hematopoietic stem or progenitor cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.

17. (new) The method according to claim 12 wherein the flt3-ligand is a recombinant human flt3-ligand.

18. (new) The method according to claim 13 wherein the flt3-ligand is a recombinant human flt3-ligand.

19. (new) The method according to claim 13 wherein the molecule is a recombinant human GM-CSF.

20. (new) The method according to claim 13 wherein the molecule is CD40 ligand.

21. (new) The method according to claim 13 wherein the molecule is c-kit ligand.

22. (new) The method according to claim 13 wherein the molecule is TNF- α .

23. (new) The method according to claim 15 wherein the flt3-ligand is a recombinant human flt3-ligand.

24. (new) The method according to claim 16 wherein the flt3-ligand is a recombinant human flt3-ligand.

25. (new) The method according to claim 16 wherein the molecule is a recombinant human GM-CSF.

26. (new) The method according to claim 16 wherein the molecule is CD40 ligand.

27. (new) The method according to claim 16 wherein the molecule is c-kit ligand.

28. (new) The method according to claim 16 wherein the molecule is TNF- α .

29. (new) A method of preparing a dendritic cell population, the method comprising contacting *in vitro* hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population, thereby generating the dendritic cell population.

30. (new) The method of claim 29, wherein the hematopoietic stem or progenitor cells have been enriched for the CD34+ phenotype.

31. (new) The method of claim 29, further comprising contacting the dendritic cells with a molecule selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 ligand, and CD40 antibody.
32. (new) The method of claim 31, wherein the molecule is GM-CSF.
33. (new) The method of claim 31, wherein the molecule is TNF- α .
34. (new) The method of claim 31, wherein the molecule is c-kit ligand.
35. (new) The method of claim 31, wherein the molecule is CD40 ligand.
36. (new) The method according to claim 29 wherein the flt3-ligand is a recombinant human flt3-ligand.